Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years.

Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D

Archives of disease in childhood1 Oct 1999Cited by 71 (Europe PMC)

PMID10490438PMCIDPMC1718086DOI10.1136/adc.81.4.329PepBankPUB-10490438

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In girls with early puberty, fourteen of 20 triptorelin recipients reached or exceeded target height.
In plain wordsIn girls with early puberty, fourteen of 20 triptorelin recipients reached or exceeded target height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableFinal height reaching target
Study
n = 20
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Measurements
Patients at or above target height
14 patients
triptorelin group (of 20)
Source sentences
Summary
Fourteen of 20 patients in group 1 and 12 of 18 patients in group 2 showed final height equal to or higher than target height.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty six consecutive girls with onset of puberty aged 7.5-8.5 years randomly divided into two groups: one treated with 3.75 mg triptorelin intramuscularly every four weeks (group 1); and the other with no treatment (group 2).
Report a problemFND-1049043806
02HumanRandomized controlled trialEfficacy outcome
In girls with early puberty, triptorelin increased age at menarche compared with no treatment.
In plain wordsIn girls with early puberty, menstruation started later with triptorelin than with no treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAge at menarche
Study
n: not reported in source
Comparator
No treatment
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Measurements
Age at menarche
11.9 years
triptorelin
Age at menarche
10.8 years
untreated
Source sentences
Summary
Mean (SD) chronological age at onset of menarche was significantly higher in group 1 than in group 2 (11.9 (1.0) v 10.8 (0.7) years).
1 context sentence(design, population, supporting numbers)
Summary · context
Forty six consecutive girls with onset of puberty aged 7.5-8.5 years randomly divided into two groups: one treated with 3.75 mg triptorelin intramuscularly every four weeks (group 1); and the other with no treatment (group 2).
Report a problemFND-1049043801
03HumanRandomized controlled trialEfficacy outcome
In girls with early puberty, height at menarche was similar with triptorelin and no treatment.
In plain wordsIn girls with early puberty, height when menstruation started was similar with triptorelin and no treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeHeight at menarche
Study
n: not reported in source
Comparator
No treatment
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Measurements
Height at menarche
152.7 cm
triptorelin
Height at menarche
152.5 cm
untreated
Source sentences
Summary
However, mean (SD) height at menarche (152.7 (7.2) v 152.5 (5.7) cm) and mean (SD) growth after menarche (4.9 (3.0) v 5.4 (2.2) cm) were similar in both groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty six consecutive girls with onset of puberty aged 7.5-8.5 years randomly divided into two groups: one treated with 3.75 mg triptorelin intramuscularly every four weeks (group 1); and the other with no treatment (group 2).
Report a problemFND-1049043802
04HumanRandomized controlled trialEfficacy outcome
In girls with early puberty, growth after menarche was similar with triptorelin and no treatment.
In plain wordsIn girls with early puberty, growth after menstruation started was similar with triptorelin and no treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeGrowth after menarche
Study
n: not reported in source
Comparator
No treatment
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Measurements
Growth after menarche
4.9 cm
triptorelin
Growth after menarche
5.4 cm
untreated
Source sentences
Summary
However, mean (SD) height at menarche (152.7 (7.2) v 152.5 (5.7) cm) and mean (SD) growth after menarche (4.9 (3.0) v 5.4 (2.2) cm) were similar in both groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty six consecutive girls with onset of puberty aged 7.5-8.5 years randomly divided into two groups: one treated with 3.75 mg triptorelin intramuscularly every four weeks (group 1); and the other with no treatment (group 2).
Report a problemFND-1049043803
05HumanRandomized controlled trialEfficacy outcome
In girls with early puberty, final height was similar with triptorelin and no treatment.
In plain wordsIn girls with early puberty, final height was similar with triptorelin and no treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFinal height
Study
n: not reported in source
Comparator
No treatment
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Measurements
Final height
158.1 cm
triptorelin
Source sentences
Summary
The mean (SD) final height was similar in the two groups (group 1, 158.1 (6.2) cm; group 2, 158. 6 (6.0) cm) and not significantly different from target height.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty six consecutive girls with onset of puberty aged 7.5-8.5 years randomly divided into two groups: one treated with 3.75 mg triptorelin intramuscularly every four weeks (group 1); and the other with no treatment (group 2).
Report a problemFND-1049043804
06HumanRandomized controlled trialEfficacy outcome
In girls with early puberty, final height after triptorelin did not differ significantly from target height.
In plain wordsIn girls with early puberty, final height after triptorelin was similar to target height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFinal height relative to target
Study
n: not reported in source
Comparator
Target height
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Measurements
Final height
158.1 cm
triptorelin
Source sentences
Summary
The mean (SD) final height was similar in the two groups (group 1, 158.1 (6.2) cm; group 2, 158. 6 (6.0) cm) and not significantly different from target height.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty six consecutive girls with onset of puberty aged 7.5-8.5 years randomly divided into two groups: one treated with 3.75 mg triptorelin intramuscularly every four weeks (group 1); and the other with no treatment (group 2).
Report a problemFND-1049043805
07HumanRandomized controlled trialEfficacy outcome
In girls with similar initial height prognosis, final heights were similar with triptorelin and no treatment.
In plain wordsIn girls with similar initial height prognosis, final heights were similar with triptorelin and no treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFinal height within initial prognosis strata
Study
n: not reported in source
Comparator
No treatment
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Source sentences
Summary
Final heights of girls with poor initial height prognosis were significantly lower than those of girls with good prognosis, but in patients with the same initial height prognosis, both groups showed final heights similar and not significantly different from their target heights.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty six consecutive girls with onset of puberty aged 7.5-8.5 years randomly divided into two groups: one treated with 3.75 mg triptorelin intramuscularly every four weeks (group 1); and the other with no treatment (group 2).
Report a problemFND-1049043807
08HumanRandomized controlled trialEfficacy outcome
In girls with early puberty, final height after triptorelin did not differ significantly from target height within initial height prognosis strata.
In plain wordsIn girls with similar initial height prognosis, final height after triptorelin did not differ significantly from target height.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFinal height relative to target within prognosis strata
Study
n: not reported in source
Comparator
Target height
Outcome group
Linear growth · Endocrine and hormones
Studied dose
3.75 mg every four weeks · intramuscularAs given in this study (human).
Source sentences
Summary
Final heights of girls with poor initial height prognosis were significantly lower than those of girls with good prognosis, but in patients with the same initial height prognosis, both groups showed final heights similar and not significantly different from their target heights.
1 context sentence(design, population, supporting numbers)
Summary · context
Forty six consecutive girls with onset of puberty aged 7.5-8.5 years randomly divided into two groups: one treated with 3.75 mg triptorelin intramuscularly every four weeks (group 1); and the other with no treatment (group 2).
Report a problemFND-1049043808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.